{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T01:30:39Z","timestamp":1776130239973,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Yang Ming Chiao Tung University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Boron neutron capture therapy (BNCT) is a targeted radiotherapy modality that has shown promise in the treatment of recurrent gliomas and head and neck cancers. Although meningiomas are generally slow-growing, recent studies have demonstrated favorable uptake of boron-containing compounds, particularly boronophenylalanine (BPA), suggesting a potential role for BNCT in recurrent meningioma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We retrospectively analyzed 13 patients with recurrent meningiomas treated with salvage BNCT at the Tsing Hua Open-Pool Reactor between August 2020 and May 2024. Tumor uptake was assessed using either \u00b9\u2078F-BPA or \u00b9\u2078F-Fluciclovine PET. Treatment response was evaluated using RANO criteria, and outcomes were analyzed in relation to dosimetric and clinical factors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 13 patients (1 WHO grade 3, 6 grade 2, and 6 grade 1), 5 (38%) responded to BNCT. Responders had significantly higher tumor mean dose (45.10 vs. 25.85 GyE, <jats:italic>p<\/jats:italic>\u2009=\u20090.003). Tumor location influenced dosimetry; non\u2013skull base tumors received higher doses and showed a trend toward better response. TNR and tumor size were not predictive of response. No severe adverse events were observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Salvage BNCT is a feasible and well-tolerated treatment for recurrent meningioma, with dose distribution and tumor location significantly influencing treatment response. Further studies are warranted to refine imaging and planning strategies, particularly for skull base lesions and in the context of Fluciclovine PET.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11060-025-05184-w","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T16:58:16Z","timestamp":1753981096000},"page":"879-886","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Recurrent meningioma treated with boron neutron capture therapy: a feasibility study with dosimetric and clinical correlates"],"prefix":"10.1007","volume":"175","author":[{"given":"Tien-Li","family":"Lan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Fu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Yen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Chi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Chieh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fong-In","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinn-Jer","family":"Peir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Shen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jen-Kun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu-Han","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Ming","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"5184_CR1","doi-asserted-by":"publisher","first-page":"CNS72","DOI":"10.2217\/cns-2021-0003","volume":"10","author":"I Maggio","year":"2021","unstructured":"Maggio I, Franceschi E, Tosoni A et al (2021) Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. CNS Oncol 10:CNS72. https:\/\/doi.org\/10.2217\/cns-2021-0003","journal-title":"CNS Oncol"},{"key":"5184_CR2","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1093\/neuonc\/noae082","volume":"26","author":"JZ Wang","year":"2024","unstructured":"Wang JZ, Landry AP, Raleigh DR et al (2024) Meningioma: international consortium on meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients. Neuro Oncol 26:1742\u20131780. https:\/\/doi.org\/10.1093\/neuonc\/noae082","journal-title":"Neuro Oncol"},{"key":"5184_CR3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.neuchi.2021.11.003","volume":"68","author":"C Champeaux-Depond","year":"2022","unstructured":"Champeaux-Depond C, Weller J, Constantinou P et al (2022) Five-year cause-specific survival after meningioma surgery. A nationwide population-based study. Neurochirurgie 68:280\u2013288. https:\/\/doi.org\/10.1016\/j.neuchi.2021.11.003","journal-title":"Neurochirurgie"},{"key":"5184_CR4","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","volume":"23","author":"R Goldbrunner","year":"2021","unstructured":"Goldbrunner R, Stavrinou P, Jenkinson MD et al (2021) EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol 23:1821\u20131834. https:\/\/doi.org\/10.1093\/neuonc\/noab150","journal-title":"Neuro Oncol"},{"key":"5184_CR5","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1227\/neu.0000000000003149","volume":"96","author":"RV Patel","year":"2025","unstructured":"Patel RV, Yao S, Aguilar Murillo E et al (2025) Spatial distribution of meningiomas: a magnetic resonance image atlas. Neurosurgery 96:769\u2013778. https:\/\/doi.org\/10.1227\/neu.0000000000003149","journal-title":"Neurosurgery"},{"key":"5184_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10143-018-0976-7","volume":"42","author":"TR Meling","year":"2019","unstructured":"Meling TR, Da Broi M, Scheie D, Helseth E (2019) Meningiomas: skull base versus non-skull base. Neurosurg Rev 42:163\u2013173. https:\/\/doi.org\/10.1007\/s10143-018-0976-7","journal-title":"Neurosurg Rev"},{"key":"5184_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-3-031-29750-2_7","volume":"1416","author":"JZ Wang","year":"2023","unstructured":"Wang JZ, Nassiri F, Saladino A, Zadeh G (2023) Surgical therapy of non-skull base meningiomas. Adv Exp Med Biol 1416:79\u201394. https:\/\/doi.org\/10.1007\/978-3-031-29750-2_7","journal-title":"Adv Exp Med Biol"},{"key":"5184_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13014-021-01759-9","volume":"16","author":"S-W Chun","year":"2021","unstructured":"Chun S-W, Kim KM, Kim M-S et al (2021) Adjuvant radiotherapy versus observation following gross total resection for atypical meningioma: a systematic review and meta-analysis. Radiat Oncol 16:34. https:\/\/doi.org\/10.1186\/s13014-021-01759-9","journal-title":"Radiat Oncol"},{"key":"5184_CR9","doi-asserted-by":"publisher","first-page":"558845","DOI":"10.3389\/fonc.2020.558845","volume":"10","author":"DC Weber","year":"2020","unstructured":"Weber DC, Bizzocchi N, Bolsi A, Jenkinson MD (2020) Proton therapy for intracranial meningioma for the treatment of primary\/recurrent disease including re-irradiation. Front Oncol 10:558845. https:\/\/doi.org\/10.3389\/fonc.2020.558845","journal-title":"Front Oncol"},{"key":"5184_CR10","doi-asserted-by":"publisher","first-page":"110271","DOI":"10.1016\/j.radonc.2024.110271","volume":"195","author":"I Desideri","year":"2024","unstructured":"Desideri I, Morelli I, Banini M et al (2024) Re-irradiation for recurrent intracranial meningiomas: analysis of clinical outcomes and prognostic factors. Radiother Oncol 195:110271. https:\/\/doi.org\/10.1016\/j.radonc.2024.110271","journal-title":"Radiother Oncol"},{"key":"5184_CR11","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1080\/0284186X.2023.2241994","volume":"62","author":"D Scartoni","year":"2023","unstructured":"Scartoni D, Giacomelli I, Pertile R et al (2023) Proton therapy re-irradiation provides promising clinical results in recurrent brain meningioma. Acta Oncol 62:1096\u20131101. https:\/\/doi.org\/10.1080\/0284186X.2023.2241994","journal-title":"Acta Oncol"},{"key":"5184_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.radonc.2010.10.010","volume":"98","author":"SE Combs","year":"2011","unstructured":"Combs SE, Kalbe A, Nikoghosyan A et al (2011) Carbon ion radiotherapy performed as re-irradiation using active beam delivery in patients with tumors of the brain, skull base and sacral region. Radiother Oncol 98:63\u201367. https:\/\/doi.org\/10.1016\/j.radonc.2010.10.010","journal-title":"Radiother Oncol"},{"key":"5184_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s11060-022-04148-8","volume":"161","author":"MJ Mair","year":"2023","unstructured":"Mair MJ, Berghoff AS, Brastianos PK, Preusser M (2023) Emerging systemic treatment options in meningioma. J Neurooncol 161:245\u2013258. https:\/\/doi.org\/10.1007\/s11060-022-04148-8","journal-title":"J Neurooncol"},{"key":"5184_CR14","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/neuonc\/noab161","volume":"23","author":"EJ Tonogai","year":"2021","unstructured":"Tonogai EJ, Huang S, Botham RC et al (2021) Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients. Neuro Oncol 23:1723\u20131735. https:\/\/doi.org\/10.1093\/neuonc\/noab161","journal-title":"Neuro Oncol"},{"key":"5184_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/14712598.2019.1559292","volume":"19","author":"CA Dasanu","year":"2019","unstructured":"Dasanu CA, Alvarez-Argote J, Limonadi FM, Codreanu I (2019) Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs. Expert Opin Biol Ther 19:99\u2013104. https:\/\/doi.org\/10.1080\/14712598.2019.1559292","journal-title":"Expert Opin Biol Ther"},{"key":"5184_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000469679","volume":"32","author":"S-I Miyatake","year":"2018","unstructured":"Miyatake S-I, Kawabata S, Hiramatsu R et al (2018) Boron neutron capture therapy of malignant gliomas. Prog Neurol Surg 32:48\u201356. https:\/\/doi.org\/10.1159\/000469679","journal-title":"Prog Neurol Surg"},{"key":"5184_CR17","doi-asserted-by":"publisher","unstructured":"Chen Y-W, Lee Y-Y, Lin C-F et al (2021) Salvage Boron neutron capture therapy for malignant brain tumor patients in compliance with emergency and compassionate use: evaluation of 34 cases in Taiwan. Biology (Basel) 10. https:\/\/doi.org\/10.3390\/biology10040334","DOI":"10.3390\/biology10040334"},{"key":"5184_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s13014-021-01968-2","volume":"16","author":"N Hu","year":"2021","unstructured":"Hu N, Tanaka H, Kakino R et al (2021) Evaluation of a treatment planning system developed for clinical boron neutron capture therapy and validation against an independent Monte Carlo dose calculation system. Radiat Oncol 16:243. https:\/\/doi.org\/10.1186\/s13014-021-01968-2","journal-title":"Radiat Oncol"},{"key":"5184_CR19","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/jrr\/rrad056","volume":"64","author":"N Hu","year":"2023","unstructured":"Hu N, Suzuki M, Masunaga S-I et al (2023) Experimentally determined relative biological effectiveness of cyclotron-based epithermal neutrons designed for clinical BNCT: in vitro study. J Radiat Res 64:811\u2013815. https:\/\/doi.org\/10.1093\/jrr\/rrad056","journal-title":"J Radiat Res"},{"key":"5184_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s11060-005-9099-4","volume":"78","author":"K Yokoyama","year":"2006","unstructured":"Yokoyama K, Miyatake S-I, Kajimoto Y et al (2006) Pharmacokinetic study of BSH and BPA in simultaneous use for BNCT. J Neurooncol 78:227\u2013232. https:\/\/doi.org\/10.1007\/s11060-005-9099-4","journal-title":"J Neurooncol"},{"key":"5184_CR21","doi-asserted-by":"publisher","first-page":"109257","DOI":"10.1016\/j.apradiso.2020.109257","volume":"165","author":"T Andoh","year":"2020","unstructured":"Andoh T, Fujimoto T, Satani R et al (2020) Preclinical study of boron neutron capture therapy for bone metastasis using human breast cancer cell lines. Appl Radiat Isot 165:109257. https:\/\/doi.org\/10.1016\/j.apradiso.2020.109257","journal-title":"Appl Radiat Isot"},{"key":"5184_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.apradiso.2014.04.007","volume":"88","author":"T Aihara","year":"2014","unstructured":"Aihara T, Morita N, Kamitani N et al (2014) BNCT for advanced or recurrent head and neck cancer. Appl Radiat Isot 88:12\u201315. https:\/\/doi.org\/10.1016\/j.apradiso.2014.04.007","journal-title":"Appl Radiat Isot"},{"key":"5184_CR23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/neuonc\/noae170","volume":"27","author":"F Sahm","year":"2025","unstructured":"Sahm F, Aldape KD, Brastianos PK et al (2025) cIMPACT-NOW update 8: clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas. Neuro Oncol 27:319\u2013330. https:\/\/doi.org\/10.1093\/neuonc\/noae170","journal-title":"Neuro Oncol"},{"key":"5184_CR24","unstructured":"INTERNATIONAL ATOMIC ENERGY AGENCY (2023) Advances in boron neutron capture therapy."},{"key":"5184_CR25","doi-asserted-by":"publisher","unstructured":"Castello A, Albano D, Muoio B et al (2023) Diagnostic accuracy of PET with 18F-Fluciclovine ([18F]FACBC) in detecting high-grade gliomas: a systematic review and meta-analysis. Diagnostics (Basel) 13. https:\/\/doi.org\/10.3390\/diagnostics13243610","DOI":"10.3390\/diagnostics13243610"},{"key":"5184_CR26","doi-asserted-by":"publisher","unstructured":"Lan T-L, Lin C-F, Lee Y-Y et al (2023) Advances in Boron neutron capture therapy (BNCT) for recurrent intracranial meningioma. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/ijms24054978","DOI":"10.3390\/ijms24054978"},{"key":"5184_CR27","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","volume":"41","author":"PY van den Wen","year":"2023","unstructured":"van den Wen PY, Youssef G et al (2023) RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults. J Clin Oncol 41:5187\u20135199. https:\/\/doi.org\/10.1200\/JCO.23.01059","journal-title":"J Clin Oncol"},{"key":"5184_CR28","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.radonc.2020.11.001","volume":"155","author":"K Hirose","year":"2021","unstructured":"Hirose K, Konno A, Hiratsuka J et al (2021) Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): an open-label phase II trial. Radiother Oncol 155:182\u2013187. https:\/\/doi.org\/10.1016\/j.radonc.2020.11.001","journal-title":"Radiother Oncol"},{"key":"5184_CR29","doi-asserted-by":"publisher","first-page":"vdab067","DOI":"10.1093\/noajnl\/vdab067","volume":"3","author":"S Kawabata","year":"2021","unstructured":"Kawabata S, Suzuki M, Hirose K et al (2021) Accelerator-based BNCT for patients with recurrent glioblastoma: a multicenter phase II study. Neurooncol Adv 3:vdab067. https:\/\/doi.org\/10.1093\/noajnl\/vdab067","journal-title":"Neurooncol Adv"},{"key":"5184_CR30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2176\/nmc.ra.2015-0297","volume":"56","author":"S-I Miyatake","year":"2016","unstructured":"Miyatake S-I, Kawabata S, Hiramatsu R et al (2016) Boron neutron capture therapy for malignant brain tumors. Neurol Med Chir (Tokyo) 56:361\u2013371. https:\/\/doi.org\/10.2176\/nmc.ra.2015-0297","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"5184_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/neuonc\/noab217","volume":"24","author":"MC Tom","year":"2022","unstructured":"Tom MC, Kotecha R (2022) Beating a benchmark: boron neutron capture therapy for recurrent and refractory meningiomas. Neuro Oncol 24:99\u2013100. https:\/\/doi.org\/10.1093\/neuonc\/noab217","journal-title":"Neuro Oncol"},{"key":"5184_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.apradiso.2015.08.006","volume":"106","author":"M Kulvik","year":"2015","unstructured":"Kulvik M, Kallio M, Laakso J et al (2015) Biodistribution of boron after intravenous 4-dihydroxyborylphenylalanine-fructose (BPA-F) infusion in meningioma and schwannoma patients: a feasibility study for boron neutron capture therapy. Appl Radiat Isot 106:207\u2013212. https:\/\/doi.org\/10.1016\/j.apradiso.2015.08.006","journal-title":"Appl Radiat Isot"},{"key":"5184_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.21037\/tro-23-38","volume":"8","author":"T-Y Huang","year":"2024","unstructured":"Huang T-Y, Wu Y-C, Chi C-T et al (2024) Nursing care for patients with recurrent invasive meningioma undergoing salvage boron neutron capture therapy: a case report. Ther Radiol Oncol 8:4\u20134. https:\/\/doi.org\/10.21037\/tro-23-38","journal-title":"Ther Radiol Oncol"},{"key":"5184_CR34","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.21037\/qims-23-1769","volume":"14","author":"K-H Lin","year":"2024","unstructured":"Lin K-H, Chen Y-W, Wang L-W et al (2024) Prognostic assessment of 18F-boronophenylalanine positron emission tomography (BPA-PET) in salvage boron neutron capture therapy for malignant brain tumors. Quant Imaging Med Surg 14:4177\u20134188. https:\/\/doi.org\/10.21037\/qims-23-1769","journal-title":"Quant Imaging Med Surg"},{"key":"5184_CR35","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.nucmedbio.2015.07.005","volume":"42","author":"M Ono","year":"2015","unstructured":"Ono M, Oka S, Okudaira H et al (2015) [(14)C]Fluciclovine (alias anti-[(14)C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells. Nucl Med Biol 42:887\u2013892. https:\/\/doi.org\/10.1016\/j.nucmedbio.2015.07.005","journal-title":"Nucl Med Biol"},{"key":"5184_CR36","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s12149-016-1102-y","volume":"30","author":"A Kondo","year":"2016","unstructured":"Kondo A, Ishii H, Aoki S et al (2016) Phase IIa clinical study of [18F]fluciclovine: efficacy and safety of a new PET tracer for brain tumors. Ann Nucl Med 30:608\u2013618. https:\/\/doi.org\/10.1007\/s12149-016-1102-y","journal-title":"Ann Nucl Med"},{"key":"5184_CR37","doi-asserted-by":"publisher","unstructured":"Scarpelli ML, Healey DR, Mehta S, Quarles CC (2022) Imaging glioblastoma with 18F-Fluciclovine amino acid positron emission tomography. Front Oncol 12. https:\/\/doi.org\/10.3389\/fonc.2022.829050","DOI":"10.3389\/fonc.2022.829050"},{"key":"5184_CR38","doi-asserted-by":"publisher","first-page":"852","DOI":"10.2967\/jnumed.122.264812","volume":"64","author":"A Nabavizadeh","year":"2023","unstructured":"Nabavizadeh A, Bagley SJ, Doot RK et al (2023) Distinguishing progression from pseudoprogression in glioblastoma using 18F-Fluciclovine PET. J Nucl Med 64:852\u2013858. https:\/\/doi.org\/10.2967\/jnumed.122.264812","journal-title":"J Nucl Med"},{"key":"5184_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.radonc.2019.04.033","volume":"137","author":"H Koivunoro","year":"2019","unstructured":"Koivunoro H, Kankaanranta L, Sepp\u00e4l\u00e4 T et al (2019) Boron neutron capture therapy for locally recurrent head and neck squamous cell carcinoma: an analysis of dose response and survival. Radiother Oncol 137:153\u2013158. https:\/\/doi.org\/10.1016\/j.radonc.2019.04.033","journal-title":"Radiother Oncol"},{"key":"5184_CR40","doi-asserted-by":"publisher","first-page":"15701","DOI":"10.1038\/s41598-023-42508-0","volume":"13","author":"Y-C Teng","year":"2023","unstructured":"Teng Y-C, Chen J, Zhong W-B, Liu Y-H (2023) HU-based material conversion for BNCT accurate dose estimation. Sci Rep 13:15701. https:\/\/doi.org\/10.1038\/s41598-023-42508-0","journal-title":"Sci Rep"},{"key":"5184_CR41","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/neuonc\/noab108","volume":"24","author":"S Takai","year":"2022","unstructured":"Takai S, Wanibuchi M, Kawabata S et al (2022) Reactor-based boron neutron capture therapy for 44 cases of recurrent and refractory high-grade meningiomas with long-term follow-up. Neuro Oncol 24:90\u201398. https:\/\/doi.org\/10.1093\/neuonc\/noab108","journal-title":"Neuro Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05184-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05184-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05184-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T06:58:56Z","timestamp":1757487536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05184-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["5184"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05184-w","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Taipei Veterans General Hospital (IRB-TPEVGH No. 2024-06-005\u00a0A, Protocol No. TBCGHPZ20231218).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}